tradingkey.logo

Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials

ReutersJan 5, 2026 2:01 PM

- Genelux Corp GNLX.O:

  • GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS

  • GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)

  • GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI